Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with multiple myeloma based on established 2016 international diagnostic guidelines.
- People whose previous treatment included a drug called lenalidomide (used continuously for at least 2 treatment cycles) as well as a type of drug called a proteasome inhibitor.
- People whose general health and ability to carry out daily activities falls within a certain range, rated 0 to 2 on a standard medical scale (confirm with trial site).
- People whose myeloma shows measurable signs of disease through at least one of the following blood or urine tests: a protein called M-protein detected at a certain level in the blood or urine, or abnormal levels of a substance called free light chains in the blood (confirm specific test values with trial site).
Who may not be able to join:
- People who have previously been treated with a drug called pomalidomide, or who were unable to tolerate it.
- People who have a condition called primary light-chain amyloidosis or plasma cell leukemia.
- People whose multiple myeloma has spread to affect the central nervous system (the brain and spinal cord).
- People who have had another type of cancer within the 3 years before starting the trial.
- People who have active bleeding in the gut, mouth, or internal organs.
- People who have previously received a treatment that specifically targets a protein called BCMA.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: （+86）13821266636
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective response rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.